期刊
ADVANCED FUNCTIONAL MATERIALS
卷 31, 期 44, 页码 -出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/adfm.202100643
关键词
galectin-3; gene therapies; neuroinflammation; pectic galactan polysaccharide; reactive gliosis
类别
资金
- Binational Science Foundation (BSF, United States - Israel) [2009178]
- Focal Technological Area (FTA) Program of the Israel National Nanotechnology Initiative (INNI)
This study introduces a novel gene therapy approach using a PG-based carrier to target reactive gliosis in neuroinflammation. The synthesized carrier, QPG, effectively condenses plasmid DNA and binds to Gal-3, demonstrating promising characteristics for targeted gene therapy applications. The in vivo study confirms the biocompatibility and selective transfection capabilities of this PG-based delivery system for treating neuroinflammation-related injuries and neurodegenerative diseases.
Treating neuroinflammation-related injuries and disorders through manipulation of neuroinflammation functions is being heralded as a new therapeutic strategy. In this study, a novel pectic galactan (PG) polysaccharide based gene therapy approach is developed for targeting reactive gliosis in neuroinflammation. Galectin-3 (Gal-3) is a cell protein with a high affinity to beta-galactoside sugars and is highly expressed in reactive gliosis. Since PG carries galactans, it can target reactive gliosis via specific carbohydrate interaction between galactan and Gal-3 on the cell membrane, and therefore can be utilized as a carrier for delivering genes to these cells. The carrier is synthesized by modifying quaternary ammonium groups on the PG. The resulting quaternized PG (QPG) is found to form complexes with plasmid DNA with a mean diameter of 100 nm and have the characteristics required for targeted gene therapy. The complexes efficiently condense large amounts of plasmid per particle and successfully bind to Gal-3. The in vivo study shows that the complexes are biocompatible and safe for administration and can selectively transfect reactive glial cells of an induced cortical lesion. The results confirm that this PG-based delivery system is a promising platform for targeting Gal-3 overexpressing neuroinflammation cells for treating neuroinflammation-related injuries and neurodegenerative diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据